Sangamo Therapeutics (SGMO) Misses Q3 EPS by 27c

Sangamo Therapeutics (NASDAQ: SGMO) reported Q3 EPS of ($0.59), $0.27 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $9.39 million versus the consensus estimate of $9.36 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c